Comparisons

Ozari vs Sequence: An Honest Comparison of GLP-1 Telehealth Services

If you're exploring GLP-1 medications like semaglutide or tirzepatide for weight loss, you've probably come across both Ozari Health and Sequence. Both offer telehealth access to these powerful medications, but they take different approaches to pricing, care, and patient support. Let's break down what really matters so you can choose the option that fits your needs and budget.

Understanding the Basics: What Both Services Offer

Both Ozari and Sequence provide access to GLP-1 receptor agonists through online consultations with licensed healthcare providers. These medications have changed the landscape of weight management, helping people achieve significant weight loss when combined with lifestyle changes.

The core offering is similar: you complete a health assessment, connect with a medical provider, and if appropriate, receive a prescription for GLP-1 medication shipped directly to your home. But the similarities largely end there.

The Price Difference You Need to Know

Let's address the elephant in the room: cost. This is often the deciding factor for many people, especially since GLP-1 therapy is typically a long-term commitment.

Ozari Health offers compounded semaglutide and tirzepatide starting at $99 per month. This straightforward pricing includes your medication, provider consultations, and ongoing support.

Sequence's pricing structure is significantly higher, with costs typically ranging from $297 to over $500 per month depending on your medication and dosage. They position themselves as a premium service with additional features, but the price point puts them out of reach for many people who could benefit from GLP-1 therapy.

What Compounded Medications Mean for Your Wallet

Both services primarily offer compounded versions of semaglutide and tirzepatide. Compounded medications are made by specialized pharmacies and contain the same active ingredients as brand-name drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.

The FDA allows compounding of medications that are on the shortage list, which has included these GLP-1 drugs. This creates legal access to more affordable versions while maintaining quality standards through licensed compounding pharmacies.

Care Approach and Medical Support

Sequence emphasizes a comprehensive approach with nutrition coaching, exercise guidance, and regular check-ins with health coaches in addition to medical provider access. This sounds appealing, but it's worth asking yourself whether you need all these extras or if you're essentially paying for services you won't use.

Ozari takes a more streamlined, doctor-forward approach. You get direct access to licensed physicians who specialize in metabolic health and GLP-1 therapy. The focus is on medical oversight, dosage optimization, and addressing side effects—the clinical essentials that actually matter for safe and effective treatment.

For many people, especially those who already have support systems or prefer to manage their own nutrition and exercise, Ozari's focused medical model makes more sense than paying extra for coaching services.

Response Time and Accessibility

Both platforms offer telehealth convenience, but accessibility goes beyond just being online. Ozari's lower price point makes ongoing treatment more sustainable for most budgets. There's no point in starting a weight loss medication if you can't afford to continue it long enough to see results and maintain them.

Medication Options and Flexibility

Both Ozari and Sequence offer access to the two main GLP-1 medications used for weight loss: semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound).

Tirzepatide is actually a dual GLP-1/GIP receptor agonist and tends to produce slightly greater weight loss results in studies, though individual responses vary. Having access to both medication options is important because what works best can differ from person to person.

Both services work with you to find the right medication and dosage, adjusting as needed based on your results and any side effects you experience.

A Note on Gender Differences

While GLP-1 medications work effectively for all genders, research suggests women may experience slightly different side effect profiles, particularly related to nausea in the early weeks of treatment. Women are also more likely to be starting GLP-1 therapy at lower BMIs for metabolic health benefits beyond just the number on the scale.

Regardless of which service you choose, make sure your provider takes time to understand your individual health history, hormone factors, and personal goals rather than applying a one-size-fits-all approach.

What Really Matters When Choosing

Skip the marketing fluff and focus on these practical factors:

The Bottom Line

Sequence may appeal to those who want an all-inclusive package with coaching and premium positioning, but you'll pay significantly more for those extras. For most people seeking effective, medically supervised GLP-1 therapy, Ozari provides the clinical essentials at a price point that makes long-term success actually achievable.

The best choice is the one you can stick with. A less expensive service that you can maintain consistently will always outperform a premium service you have to stop after a few months due to cost.

From the Ozari Care Team

Many patients ask us about switching from higher-priced services to Ozari. The transition is straightforward, and your progress doesn't reset. We review your previous dosing and adjust accordingly, ensuring continuity of care without the premium price tag. Remember, consistency matters more than perfection when it comes to achieving your metabolic health goals.

Ready to start your GLP-1 journey? At Ozari Health we offer compounded Semaglutide and Tirzepatide starting at $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.


Medically reviewed by the Ozari Clinical Care Team, licensed physicians specializing in metabolic health and GLP-1 therapy. Last reviewed: April 29, 2026